Compare PSTL & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTL | ADCT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.6M | 484.4M |
| IPO Year | 2018 | 2019 |
| Metric | PSTL | ADCT |
|---|---|---|
| Price | $21.22 | $3.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $20.19 | $7.75 |
| AVG Volume (30 Days) | 194.1K | ★ 891.7K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | ★ 123.81 | 30.86 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $95,823,000.00 | $81,357,000.00 |
| Revenue This Year | $18.01 | N/A |
| Revenue Next Year | $11.38 | $66.49 |
| P/E Ratio | $46.09 | ★ N/A |
| Revenue Growth | ★ 25.47 | 14.85 |
| 52 Week Low | $12.26 | $1.23 |
| 52 Week High | $21.95 | $4.98 |
| Indicator | PSTL | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 61.51 | 42.38 |
| Support Level | $18.24 | $3.65 |
| Resistance Level | N/A | $3.88 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 69.69 | 9.96 |
Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).